2 results
Approved WMOCompleted
First, to demonstrate whether UDCA-therapy is effective in reducing total liver volume in PLD patients. Second, we want to assess if UDCA modifies quality of life. Finally, we want to assess safety and tolerability.
Approved WMORecruiting
The primary objective of this trial is:• Part 1 (dose-escalation): To evaluate the safety of BYON3521 and to determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE); • Part 2 (expansion): To evaluate the objective tumour…